Medicus pharma ltd announces positively trending interim analysis for sknjct-003 phase 2 clinical study to non-invasively treat basal cell carcinoma of the skin (bcc)

The interim analysis showed complete clinical clearance of more than sixty (60%) percent philadelphia, pennsylvania--(newsfile corp. - march 6, 2025) - medicus pharma ltd. (nasdaq: mdcx) ("medicus" or the "company") is pleased to announce a positively trending interim analysis for sknjct-003 phase 2 clinical study to non-invasively treat basal cell carcinoma of the skin (bcc).
BCC Ratings Summary
BCC Quant Ranking